Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;21(12):2002-2013.
doi: 10.1038/s41589-025-02058-0. Epub 2025 Nov 21.

SINE compounds activate exportin 1 degradation through an allosteric mechanism

Affiliations

SINE compounds activate exportin 1 degradation through an allosteric mechanism

Casey E Wing et al. Nat Chem Biol. 2025 Dec.

Abstract

Overexpression of exportin 1 (XPO1/CRM1) in cancer cells mislocalizes numerous cancer-related nuclear export cargoes. Covalent selective inhibitors of nuclear export (SINEs), including the cancer drug selinexor, restore proper nuclear localization by blocking XPO1-cargo interaction. These inhibitors also induce XPO1 degradation through the Cullin-RING E3 ligase (CRL) substrate receptor ASB8. Here we present cryo-electron microscopy structures revealing ASB8 binding to a cryptic XPO1 site that is exposed upon SINE conjugation. Unlike typical molecular glue degraders that directly bridge CRLs and substrates, SINEs bind XPO1 independently of ASB8, triggering an allosteric mechanism that enables high-affinity ASB8 recruitment, leading to XPO1 ubiquitination and degradation. ASB8-mediated degradation is also triggered by the endogenous itaconate derivative 4-octyl itaconate, suggesting that synthetic XPO1 inhibitors exploit a native cellular mechanism. This allosteric XPO1 degradation mechanism expands known modes of targeted protein degradation beyond molecular glue degraders and proteolysis-targeting chimeras of CRL4.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Y.M.C. was a consultant to and holds equity options in Karyopharm Therapeutics. Y.M.C. is also a consultant to Telo Therapeutics. B.K., M.J., B.P. and D.D. are employees of KU Leuven, which has a license agreement on KPT-SINE–XPO1 inhibitors. Y.L. was an employee of Karyopharm Therapeutics and still retains ownership of company shares. S.S. is a former employee of Karyopharm Therapeutics, holds patents (8999996, 9079865, 9714226, PCT/US12/048319 and I574957) on hydrazide-containing nuclear transport modulators and uses and holds pending patents (PCT/US12/048319, 499/2012, PI20102724 and 2012000928) on hydrazide-containing nuclear transport modulators and uses. The other authors declare no competing interests.

References

    1. Wing, C. E., Fung, H. Y. J. & Chook, Y. M. Karyopherin-mediated nucleocytoplasmic transport. Nat. Rev. Mol. Cell Biol. 23, 307–328 (2022). - PubMed - PMC - DOI
    1. Monecke, T. et al. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324, 1087–1091 (2009). - PubMed - DOI
    1. Dian, C. et al. Structure of a truncation mutant of the nuclear export factor CRM1 provides insights into the auto-inhibitory role of its C-terminal helix. Structure 21, 1338–1349 (2013). - PubMed - DOI
    1. Koyama, M. & Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002–2013 (2010). - PubMed - PMC - DOI
    1. Azmi, A. S., Uddin, M. H. & Mohammad, R. M. The nuclear export protein XPO1—from biology to targeted therapy. Nat. Rev. Clin. Oncol. 18, 152–169 (2021). - PubMed - DOI

MeSH terms

LinkOut - more resources